Pathogenesis of polycystic ovary syndrome: The enigma unravels?

Lancet

Volumn 354, Issue 9183, 1999, Pages 966-967

  Balen, Adam ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LUTEINIZING HORMONE;

BODY WEIGHT; CLINICAL FEATURE; EUROPE; FEMALE; FEMALE INFERTILITY; HUMAN; INSULIN BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; NORTH AMERICA; NOTE; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; STEROIDOGENESIS; SYMPTOM;

EID: 0033581458     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00218-4     Document Type: Note

References (15)

1. Balen A.H., Conway G.S., Kaltsas G.et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 10:1995;2705-2712.
2. Homburg R. Polycystic ovary syndrome - from gynaecological curiosity to multiystem endocrinopathy. Hum Reprod. 10:1996;29-39.
3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implication for pathogenesis. Endocr Rev. 18:1997;774-800.
4. Franks S., Gharani N., Waterworth D.et al. The genetic basis of polycystic ovary syndrome. Hum Reprod. 12:1997;2641-2648.
5. Clark A.M., Ledger W., Galletly C.et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod. 10:1995;2705-2712.
6. Jacobs H.S., Conway G.S. Leptin, polycystic ovaries and polycystic ovary syndrome. Hum Reprod Update. 5:1999;166-171.
7. Balen A.H., Tan S.L., Jacobs H.S. Hypersecretion of luteinizing hormone: a significant cause of infertility and miscarriage. Br J Obstet Gynaecol. 100:1993;1082-1089.
8. Lockwood G.M., Muttukrishna S., Groome N.P., Matthews D.R., Ledger W.L. Mid-follicular phase pulses of inhibin B are absent in polycystic ovary syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism for the emergence of the dominant follicle. J Clin Endocrinol Metab. 83:1998;1730-1735.
9. Tapanainen J.S., Koivunen R., Fauser B.C.et al. A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone. J Clin Endocrinol Metab. 84:1999;1711-1715.
10. Ong K.K.L., Phillips D.I., Fall C.et al. The insulin gene VNTR, type 2 diabetes and birth weight. Nat Genet. 21:1999;262-263.
11. Waterworth D.M., Bennett S.T., Gharani N.et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet. 349:1997;986-989.
12. Polson D.W., Wadsworth J., Adams J., Franks S. Polycystic ovaries: a common finding in normal women. Lancet. ii:1988;870-872.
13. Michelmore, K.F., Balen, A.H., Dunger, D.B., Vessey, M.P. Polycystic ovaries and associated clinical and biochemical features in young women in the normal population. Clin Endocrinol (in press).
14. Velasquez E.M., Mendoza S., Hamer T., Sosa F., Glueck C.J. Metformin therapy in polycystic ovaries reduces hyperinsulinaemia, insulin resistance, hyperandrogenaemia and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 43:1994;647-654.
15. Nestler J.E., Jakubowicz D.J., Reamer P., Gunn M.S., Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 340:1999;1314-1320.